BioSpace News Archive

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in two upcoming virtual investor conferences, with additional details below.

Today, CareDx, the leading partner in transplant care, and IDbyDNA, the company revolutionizing the use of precision metagenomics, announced an exclusive partnership focused on the development of metagenomic infectious disease testing specific to transplant patients.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has signed an exclusive Supply, Distribution and Services Agreement with Daavlin.

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 85,250 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Cyclica announced the election of Sastry Chilukuri to its Board of Directors effective immediately. Chilukuri was also appointed to the Compensation and Governance sub-committees.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, met its primary and both secondary endpoints at nine months in patients with hATTR amyloidosis with polyneuropathy.

Fiscal 2021 Second Quarter Highlights Net sales of $72.8 million increased 4.0% compared to the prior-year quarter Gross margin declined 410 basis points year over year to 55.2% GAAP loss per share of $0.11 and adjusted earnings per share of $0.01 Cash and cash equivalents on November 30, 2020 were $58.0 million, compared to $47.9 million on August 31, 2020 The Company reaffirms its guidance of fiscal year 2021

Proceeds will enable advancement and acceleration of the Company’s transformative drug discovery programs derived from digital search of the fungal biosphere to discover and develop highly impactful precision medicines Significant recent scientific and operational progress includes acquisition of exquisitely biodiverse fungal strain collections amassed by Merck and Pfizer, among others, and the appointment of Nobel Laureate William G. Kaelin, Jr.,

Oragenics, Inc. announced entering into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the Company’s Terra CoV-2 vaccine against COVID-19.

Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor.